From: Farber disease: clinical presentation, pathogenesis and a new approach to treatment
Parameter | Patients | |||||||
---|---|---|---|---|---|---|---|---|
Patient number and gender | #1, female | #2, male | #3, female | #4, female | ||||
Patient origin | Muenster | Muenster | Muenster | Hamburg | ||||
Time point of follow-up | prior to SCT | day +450 | prior to SCT | day +200 | prior to SCT | day +270 | prior to SCT | day +958 |
ESR (mm, first hour, Westergren) | 38 | 9 | 53 | 12 | 25 | 13 | no data available | |
Time point of follow-up | prior to SCT | day +1800 | prior to SCT | day +1560 | prior to SCT | day +990 | prior to SCT | day +958 |
Number of nodules | 58 | 0 | 39 | 0 | 18 | 0 | pre Tx-nodules mainly dissolved, no new nodules | |
Number of joints with restricted mobility | 26 | 0 | 24 | 0 | 10 | 0 | almost all joints affected, however considerable improvement after HSCT |